Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer

Conclusion
YTHDF1 impairs antitumour immunity via an m6A-p65-CXCL1/CXCR2 axis to promote CRC and serves as a therapeutic target in immune checkpoint blockade therapy.

Source: Gut - July 6, 2023 Category: Gastroenterology Authors: Bao, Y., Zhai, J., Chen, H., Wong, C. C., Liang, C., Ding, Y., Huang, D., Gou, H., Chen, D., Pan, Y., Kang, W., To, K. F., Yu, J. Tags: Open access, Gut Colon Source Type: research